Eli Lilly Expands Portfolio with $3.8 Billion Vaccine Investment

US-based pharmaceutical giant Eli Lilly is strengthening its presence in vaccines and infectious diseases through a strategic acquisition move. The company announced a $3.8 billion investment in this context. This move is seen as part of Eli Lilly's strategy to diversify its existing drug portfolio and develop solutions for infectious diseases. With the acquisition, the company aims to gain new capabilities in vaccine technologies and infectious disease treatments. According to the details of the investment, Eli Lilly intends to build a more resilient structure against global health crises with this step. Company officials stated that the acquisition will increase R&D capacity and contribute to the development of next-generation vaccines. Financial analysts indicate that an investment of this magnitude aligns with Eli Lilly's long-term growth goals and could enhance the company's competitive edge. The acquisition is expected to be completed following regulatory approvals. This is not investment advice.